LABORATORIO FARMACEUTICO ERFO S.P.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.095 EUR | 0.00% |
|
-5.60% | -16.41% |
| Jul. 01 | ITALY GROWTH WINNERS & LOSERS: Espe on top; Redfish bad | AN |
| Jun. 04 | Erfo, MIMIT grant facilities for Plants project. | AN |
| Sales 2024 * | 6.5M 7.04M | Sales 2025 * | 7.4M 8.02M | Capitalization | 9.42M 10.21M |
|---|---|---|---|---|---|
| Net income 2024 * | - 0 | Net income 2025 * | - 0 | EV / Sales 2024 * | 1.14 x |
| Net cash position 2024 * | 2M 2.17M | Net cash position 2025 * | 2.5M 2.71M | EV / Sales 2025 * | 0.93 x |
| P/E ratio 2024 * |
18.3
x | P/E ratio 2025 * |
15.6
x | Employees | 33 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 20.38% |
More Fundamentals
* Assessed data
More news
| 1 week | -5.60% | ||
| Current month | -5.60% | ||
| 1 month | -3.10% | ||
| 3 months | -3.52% | ||
| 6 months | -7.98% | ||
| Current year | -16.41% |
1 week
1.08
1.24
1 month
1.071.24
Current year
0.971.33
1 year
0.881.34
3 years
0.883.30
5 years
0.883.30
10 years
0.883.30
| Managers | Title | Age | Since |
|---|---|---|---|
Flavio Corpina
CEO | Chief Executive Officer | 45 | 16-12-31 |
Alessandro Cutè
CEO | Chief Executive Officer | 54 | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alessandro Cutè
CEO | Chief Executive Officer | 54 | 12-12-31 |
Flavio Corpina
CEO | Chief Executive Officer | 45 | 16-12-31 |
Fabio Giuffre
BRD | Director/Board Member | 43 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-05 | 1.095 | 0.00% | 0 |
| 24-07-04 | 1.095 | 0.00% | 2,000 |
| 24-07-03 | 1.095 | -0.45% | 29,000 |
| 24-07-02 | 1.1 | -1.79% | 11,000 |
| 24-07-01 | 1.12 | -3.45% | 77,000 |
Real-time Borsa Italiana, July 05, 2024 at 11:44 am EDT
More quotes
Laboratorio Farmaceutico Erfo SpA is an Italy-based pharmaceutical company primarily engaged in the nutraceutical sector. The Company specializes in the production of nutritional supplements, that thanks to research and development carried out internally and in collaboration with the University Campus Bio-Medico of Rome and the University of Messina provides products with a scientific value in different therapeutic areas. The Company operates globally.
Sector
Pharmaceuticals
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.095
EUR
Average target price
1.47
EUR
Spread / Average Target
+34.25%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -16.41% | 10.19M | |
| +56.89% | 823B | |
| +39.52% | 627B | |
| -6.55% | 353B | |
| +15.99% | 320B | |
| +7.92% | 295B | |
| +13.74% | 239B | |
| +13.83% | 220B | |
| -0.49% | 219B | |
| +7.94% | 167B |
- Stock Market
- Equities
- ERFO Stock
